Ulysses Neuroscience Limited

🌍 World Mental Health Day 2024 🌍 #WorldMentalHealthDay 💚 is celebrated on October 10th across the globe with the goal of promoting, educating, and raising awareness of mental health issues. The 2024 theme, "𝗜𝘁 𝗶𝘀 𝗧𝗶𝗺𝗲 𝘁𝗼 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗲 𝗠𝗲𝗻𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗶𝗻 𝘁𝗵𝗲 𝗪𝗼𝗿𝗸𝗽𝗹𝗮𝗰𝗲", reminds us of the critical role mental well-being plays in a healthy work environment. 🫂 ☺️ Supporting mental health at work is not just an option, it’s a necessity. #MentalHealthMatters #WorkplaceWellbeing #SupportMentalHealth #WorldMentalHealthDay2024

Join us this October in raising awareness for Charcot-Marie-Tooth (#CMT) Disease 💙 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗖𝗠𝗧? Charcot-Marie-Tooth disease is a rare neurological condition that affects the nerves in the arms and legs. As the nerves deteriorate, it leads to muscle wasting and weakness, primarily in the lower legs/feet and lower arms/hands, resulting in varying degrees of disability. Around 2.8 million people 🧑🤝🧑 worldwide are affected by #CMT, making daily activities more difficult. By raising awareness, we not only foster early diagnosis 🧠 but also drive research 🔬 and provide support for those living with this progressive condition. 𝗪𝗵𝗮𝘁 𝗰𝗮𝗻 𝘄𝗲 𝗱𝗼? Show solidarity 🤝 with those living with CMT and let them know they are not alone. Speaking out is not just about raising awareness, it’s about creating change and breaking the silence around them. At Ulysses Neuroscience, we are dedicated to pushing the boundaries of research in the pursuit of a cure for #CharcotMarieTooth (CMT) Disease. 📨 Contact us to learn more about our studies. Together, we can make a difference. 💪 #CharcotMarieTooth #RareDisease #Neuroscience #Neuropathies

✨ Meet us at Booth #259 to discover more about our cutting-edge research. You can just pass by or book a meeting by clicking here: 👉 https://lnkd.in/db5XT2pX Ulysses's team is excited to present groundbreaking research and demonstrate our neuroscience capabilities as we advance the field throughout the conference. We will feature four scientific posters: Presenter: Dr. Massimiliano (Massi) Bianchi, PhD "Plastinogenic Effects of Ketamine on Primary Mouse Cortical Neurons: Establishing a Platform for Novel Antidepressant Discovery" 📍 Board B62 - Oct 5, 1-5 PM Presenter: Dr. Shani Waninger "Preclinical and Clinical evidence on Alpha-Tubulin Post-translational Modifications as Potential Translational Biomarkers in CDKLS Deficiency Disorder" 📍 Board A16 - Oct 6, 1-5 PM Presenter: Dr. Shani Waninger "Neurolinguistic and Blood Biomarkers in Fragile X and Fragile X Premutation Carriers" 📍 Board A55 - Oct 8, 2024, 1-5 PM Presenter: Dr. Enya Paschen, PhD, "Interferon-alpha administration in rats as a model capturing the Yin and Yang of depression: effects of acute ketamine" 📍 Board A08 - Oct 8, 1-5 PM 🤝 Don’t miss this opportunity to connect with us! #Neuroscience #SfN #Neuropsychiatry #Plasticity #Biomarkers

🌟We are delighted to share our recent progress in the identification of key biomarkers aimed at enhancing the early diagnosis and treatment of CMT. 🧬Dr. Nadia Boulahia, our expert in immunogenetics research and diseases, presented promising new insights at the Congresso Medico in Bologna last September 29th, organized by ACMT-Rete per la Malattia di Charcot-Marie-Tooth. 💡 This study marks a significant milestone as it is the first observational biomarker study on the Irish cohort for #CMT, now conducted across two additional sites: Ospedale San Raffaele in Milan, and Tallaght University Hospital in Dublin. 📨 Contact us to learn more about this innovative study in CMT. #Neuroscience #CMT1A #Biomarkers #TranslationalResearch #ACMT

🌐 Delighted to have presented at the 𝟳𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗡𝗲𝘂𝗿𝗼𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 in Boston! Our Biomarker & Cell Culture Team Leader, Dr. Connor Maltby, and Founder / President & CEO, Prof. Massimiliano (Massi) Bianchi, PhD, showcased our cutting-edge research to a room full of inspiring leaders and scientists. 🔬🧠 The insights into the expanding potential of #psychedelics and psychedelic-derived therapies for #neuropsychiatric, neurodegenerative, and developmental disorders were both exciting and impactful. Next stop? Join us The Society for Neuroscience Conference in Chicago starting on October 5th 📅 Secure your spot to meet with our team 👉 https://lnkd.in/db5XT2pX #Neuroscience #PsychedelicTherapies #Neuroplasticity #SfN #DrugDevelopment #TranslationalResearch #Biomarkers

Join us on Thursday at the '7th Annual Neuropsychiatric Drug Development Summit'! Our Biomarker & Cell culture Team Leader, Connor Maltby, will be presenting our new clinical and preclinical biomarker work: 🔬 𝘔𝘪𝘤𝘳𝘰𝘵𝘶𝘣𝘶𝘭𝘦 𝘱𝘳𝘰𝘵𝘦𝘪𝘯𝘴 𝘢𝘴 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘢𝘯𝘥 𝘱𝘦𝘳𝘪𝘱𝘩𝘦𝘳𝘢𝘭 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳𝘴 𝘰𝘧 𝘯𝘦𝘶𝘳𝘰𝘱𝘭𝘢𝘴𝘵𝘪𝘯𝘰𝘨𝘦𝘯 𝘦𝘧𝘧𝘪𝘤𝘢𝘤𝘺: 𝘱𝘳𝘦𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦. 📅 Mark your calendar: 10:50 am Eastern Time on Thursday, 26th September, in Boston (US). Schedule a meeting with our expert team at the conference! Click here👉 https://lnkd.in/db5XT2pX We look forward to seeing you in the US soon! #Neuroscience #CDKL5 #Biomarkers #EEG #ClinicalResearch #Neurodevelopment #Neuroplasticity #Neuropsychiatry #BehavioralResearch #TranslationalResearch

We are happy to announce that Ulysses Neuroscience Ltd. has obtained ethical approval for the #CDKL5 biomarker study at Hospital in Borgo Trento (Verona), Italy. This approval is part of the ELPIS study, which brings hope to patients suffering from CDKL5 Deficiency Disorder (CDD). #ELPIS is the first of its kind, with a mission to validate innovative biomarkers for CDD, focusing on: 📌 Plasma Microtubule Proteins 📌 Neurological Plasma Biomarkers The ELPIS research, supported by the 𝐋𝐨𝐮𝐥𝐨𝐮 𝐅𝐨𝐮𝐧𝐝𝐚𝐭𝐢𝐨𝐧, is expanding across seven countries and has now covered two cities in Italy — Milan was our first Italian city, and now Borgo Trento in Verona. As a company dedicated to advancing research on brain disorders, we are excited to lead this ground-breaking study — the first age/gender-matched control biomarker study in Italy. 📧 Contact us to learn more about this pioneering study in CDKL5. Together, we can make a difference! 💪 #Neuroscience #CDKL5 #ELPIS #TranslationalResearch #Neuroplasticity #CRO #CDD

At Ulysses Neuroscience, we are experiencing the most exciting period since our inception in 2019. 🚀🧠 We are advancing our research platforms in #neuropsychiatric, neurovelopmental disorders, #psychedelics, neuronal plasticity, and neuroinflammation. From global clinical biocollection to cell culture and in-vivo disease models, and an extensive molecular and neurophysiological biomarker platform, Ulysses Neuroscience Ltd. stands out as your unique Vanguard CRO and Translational Partner. 🌟 Curious to learn more? Starting September 24th, our team will be touring Boston and Chicago 🦅, attending several key events: 📅 ✔️ The 𝟳𝘁𝗵 𝗡𝗲𝘂𝗿𝗼𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 in Boston (September 24-26) ✈️ ✔️ The 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗳𝗼𝗿 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟰 in Chicago at booth 259 (October 5–9) 🏙️ ✔️ The 𝗖𝗗𝗞𝗟𝟱 𝗙𝗼𝗿𝘂𝗺 in Boston (October 27–29) 👉 Schedule a time to connect with our team here: https://lnkd.in/db5XT2pX We look forward to seeing you in the US soon! #Neuroscience #CDKL5 #NeuroPlasticity #CRO #TranslationalResearch

Ulysses Neuroscience Ltd., your Vanguard CRO and Translational Partner, is excited to announce our upcoming US tour starting on September 24th, marking a new phase of growth and innovation in our research platforms focused on neuropsychiatry and neurodevelopmental diseases. Our team will be unveiling our latest preclinical and clinical data at several key events:  📅 the 𝟳𝘁𝗵 𝗡𝗲𝘂𝗿𝗼𝗽𝘀𝘆𝗰𝗵𝗶𝗮𝘁𝗿𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 in Boston (September 24-26), the 𝗦𝗼𝗰𝗶𝗲𝘁𝘆 𝗳𝗼𝗿 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟰 in Chicago at booth 259 (October 5–9), and the 𝗖𝗗𝗞𝗟𝟱 𝗙𝗼𝗿𝘂𝗺 in Boston (October 27–29). We’re eager to connect with our colleagues and clients who are interested in learning more about our new services. Joining our founder, Prof. Massimiliano (Massi) Bianchi, PhD, will be Dr. Enya Paschen, PhD (Behavioral Pharmacology/EEG Team Leader), Dr. Connor Maltby (Biomarker/Cell Culture Team Leader) and Dr Shani Waninger (Senior Business Development and Clinical Director). 🌟 Don’t miss the chance to meet with our team of experts.  👉 Book your meeting here: https://lnkd.in/db5XT2pX We look forward to seeing you in the US soon! #Neuroscience #EEG #DrugDiscovery #Biomarkers #SFN #CDKL5 #ClinicalResearch #Pharmacology #Neurodevelopment #Neuropsychiatry #BehavioralResearch #TranslationalResearch

At Ulysses Neuroscience, we know that skilled individuals drive impactful results. Meet Enya Paschen, PhD, our Behavioural Pharmacology/EEG Team Leader. Enya recently relocated from 🏛️ Germany to ☘️ Ireland, drawn by her strong belief in Ulysses Neuroscience’s #mission and the impact we’re making. 🗣️ Enya shared, "Together with our clients, we will pave new pathways to accelerate drug discovery in neuroscience for the benefit of the patient community." She is excited to work alongside our clients to pioneer new approaches and speed up drug discovery for the benefit of the #PatientCommunity. 🔗 Connect with our talented team to see how we’re advancing innovation in neuroscience by visiting our website here 👉 https://ulysses-neuro.ie #Neuroscience #DrugDiscovery #Pharmacology #EEG #TeamUlysses #Innovation #Research #Psychedelics #NeurodevelopmentalDiseases